Figure 4: CD19^KO PCs engineered to secrete αCD19 bispecific have anti-lymphoma efficacy in vivo.

A) Schematic showing an in vivo model for lymphoma growth. Briefly, GFP.CD19^KO or αCD19.GFP.CD19^KO ePCs, autologous T cells, and luciferase expressing Raji cells were injected subcutaneously into the right flank of immunodeficient NSG mice. B) Representative bioluminescence images were obtained via in vivo imaging (color scale; min:8×10³ max:1×10⁵). C) Bioluminescence was quantified from each mouse as total flux and graphed over time. D) Area under the curve analysis was conducted with baseline correction of 6×10⁵ flux. A-D) Data across 4 donors in two independent experiments with p-value calculated by unpaired student’s t test. Illustrations created in part with biorender.com.